ORIC Oric Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ORIC

Price (delayed)

$16.23

Market cap

$638.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.7

Enterprise value

$468.05M

ORIC Pharmaceuticalsis a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist ...

Highlights
The EPS has soared by 79% year-on-year but it has declined by 2.3% since the previous quarter
Oric Pharmaceuticals's equity has increased by 32% YoY but it has decreased by 6% QoQ
ORIC's net income has dropped by 162% year-on-year and by 12% since the previous quarter
The quick ratio has declined by 27% since the previous quarter and by 23% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://oricpharma.com
Peers: OTIC

Key stats

What are the main financial stats of ORIC
Market
Shares outstanding
39.32M
Market cap
$638.13M
Enterprise value
$468.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$91.33M
EBITDA
-$90.4M
Free cash flow
-$59.3M
Per share
EPS
-$2.7
Free cash flow per share
-$1.62
Book value per share
$7.04
Revenue per share
$0
TBVPS
$7.31
Balance sheet
Total assets
$268.23M
Total liabilities
$9.9M
Debt
$0
Equity
$258.32M
Working capital
$255.05M
Liquidity
Debt to equity
0
Current ratio
26.75
Quick ratio
26.36
Net debt/EBITDA
1.88
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-35%
Return on equity
-36.2%
Return on invested capital
-61.4%
Return on capital employed
-35.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORIC stock price

How has the Oric Pharmaceuticals stock price performed over time
Intraday
-1.04%
1 week
4.98%
1 month
-35.24%
1 year
-30.49%
YTD
-52.05%
QTD
-22.38%

Financial performance

How have Oric Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$91.49M
Net income
-$91.33M
Gross margin
N/A
Net margin
N/A
ORIC's net income has dropped by 162% year-on-year and by 12% since the previous quarter
The operating income has dropped by 153% year-on-year and by 12% since the previous quarter

Growth

What is Oric Pharmaceuticals's growth rate over time

Valuation

What is Oric Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 79% year-on-year but it has declined by 2.3% since the previous quarter
The stock's P/B is 34% less than its last 4 quarters average of 3.5
Oric Pharmaceuticals's equity has increased by 32% YoY but it has decreased by 6% QoQ

Efficiency

How efficient is Oric Pharmaceuticals business performance
The return on equity has dropped by 103% year-on-year and by 5% since the previous quarter
The ROA has dropped by 102% year-on-year and by 5% since the previous quarter
Oric Pharmaceuticals's return on invested capital has increased by 4.7% QoQ

Dividends

What is ORIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORIC.

Financial health

How did Oric Pharmaceuticals financials performed over time
ORIC's total liabilities has soared by 58% YoY and by 26% QoQ
The total assets has grown by 33% year-on-year but it has declined by 6% since the previous quarter
ORIC's debt is 100% smaller than its equity
Oric Pharmaceuticals's equity has increased by 32% YoY but it has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.